Sirolimus Does Not Absolutely Abolish the Occurrence/Recurrence of Urothelial Carcinoma in Renal Transplant Recipients

Transplantation Proceedings

Volumn 40, Issue 7, 2008, Pages 2395-2396

  Wang, S M ^a   Tai, H C ^a,b   Chueh, S C ^a   Chung, S D ^a,b   Lai, M K ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BASILIXIMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID;

ADULT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; UROGENITAL TRACT CANCER;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 51449117923     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.06.031     Document Type: Article

References (7)

1. Liao C.H., Chueh S.C., Lai M.K., et al. Transitional cell carcinoma in renal transplant recipients. Transplant Proc 36 (2004) 2152
2. Luan F.L., Hojo M., Maluccio M., et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565
3. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 8 (2002) 128
4. Kahan B.D., Knight R., Schoenberg L., et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 35 (2003) 25S
5. Morales J.M., Wramner L., Kreis H., et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2 (2002) 436
6. Guba M., Graeb C., Jauch K.W., et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77 (2004) 1777
7. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760